Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in folfox chemotherapy for metastatic colorectal cancer

Daniel A. Goldstein, Qiushi Chen, Turgay Ayer, David H. Howard, Joseph Lipscomb, R. Donald Harvey, Bassel F. El-Rayes, Christopher R. Flowers

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Dosing chemotherapy based on pharmacokinetics (PK) instead of body surface area (BSA) has been shown to decrease interindividual variability in drug exposure. PK-guided 5-fluorouracil (5-FU) instead of BSA-guided 5- FU for patients with metastatic colorectal cancer (mCRC) leads to decreased toxicity and increased overall survival (OS). In this article, we use Markov modeling to show that this is a cost-effective strategy, costing $23,000 per quality-adjusted life-year (QALY) gained. Background: Dosing chemotherapy based on BSA results in marked interindividual variability in drug exposure. A randomized trial showed increased OS and decreased toxicity with PK-guided compared with BSA-based 5-FU dosing in patients with mCRC. The objective of this study was to compare the cost effectiveness of PK-based 5- FU dosing with BSA-based 5-FU dosing in patients with mCRC receiving FOLFOX (5-FU, leucovorin, and oxaliplatin). Materials and Methods: We developed a Markov model to evaluate the cost effectiveness of PK FOLFOX compared with BSA FOLFOX. Progression risks and cause-specific mortality were extrapolated from the fitted survival models. Costs for administration and management of adverse events were estimated based on 2013 Medicare reimbursement rates and average sale prices. Results: PK FOLFOX provided 2.03 QALYs at a cost of $50,205 compared with BSA FOLFOX, which provided 1.46 QALYs at a cost of $37,173. The incremental cost-effectiveness ratio (ICER) was $22,695 per QALY. The ICER remained < $50,000 per QALY in all univariate and multivariate sensitivity analyses. Conclusion: At a $50,000 per QALY threshold, PK FOLFOX is cost effective for mCRC. Because of the cost effectiveness profile and OS advantage with PK FOLFOX, it should be evaluated further in comparative effectiveness studies.

Original languageEnglish (US)
Pages (from-to)219-225
Number of pages7
JournalClinical Colorectal Cancer
Volume13
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Body Surface Area
Fluorouracil
Cost-Benefit Analysis
Quality-Adjusted Life Years
Colorectal Neoplasms
Pharmacokinetics
Drug Therapy
Costs and Cost Analysis
oxaliplatin
Survival
Leucovorin
Medicare
Pharmaceutical Preparations
Multivariate Analysis
Mortality

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology

Cite this

Goldstein, Daniel A. ; Chen, Qiushi ; Ayer, Turgay ; Howard, David H. ; Lipscomb, Joseph ; Harvey, R. Donald ; El-Rayes, Bassel F. ; Flowers, Christopher R. / Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in folfox chemotherapy for metastatic colorectal cancer. In: Clinical Colorectal Cancer. 2014 ; Vol. 13, No. 4. pp. 219-225.
@article{1e6bb21949db4d9daae8d2ad33a60f70,
title = "Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in folfox chemotherapy for metastatic colorectal cancer",
abstract = "Dosing chemotherapy based on pharmacokinetics (PK) instead of body surface area (BSA) has been shown to decrease interindividual variability in drug exposure. PK-guided 5-fluorouracil (5-FU) instead of BSA-guided 5- FU for patients with metastatic colorectal cancer (mCRC) leads to decreased toxicity and increased overall survival (OS). In this article, we use Markov modeling to show that this is a cost-effective strategy, costing $23,000 per quality-adjusted life-year (QALY) gained. Background: Dosing chemotherapy based on BSA results in marked interindividual variability in drug exposure. A randomized trial showed increased OS and decreased toxicity with PK-guided compared with BSA-based 5-FU dosing in patients with mCRC. The objective of this study was to compare the cost effectiveness of PK-based 5- FU dosing with BSA-based 5-FU dosing in patients with mCRC receiving FOLFOX (5-FU, leucovorin, and oxaliplatin). Materials and Methods: We developed a Markov model to evaluate the cost effectiveness of PK FOLFOX compared with BSA FOLFOX. Progression risks and cause-specific mortality were extrapolated from the fitted survival models. Costs for administration and management of adverse events were estimated based on 2013 Medicare reimbursement rates and average sale prices. Results: PK FOLFOX provided 2.03 QALYs at a cost of $50,205 compared with BSA FOLFOX, which provided 1.46 QALYs at a cost of $37,173. The incremental cost-effectiveness ratio (ICER) was $22,695 per QALY. The ICER remained < $50,000 per QALY in all univariate and multivariate sensitivity analyses. Conclusion: At a $50,000 per QALY threshold, PK FOLFOX is cost effective for mCRC. Because of the cost effectiveness profile and OS advantage with PK FOLFOX, it should be evaluated further in comparative effectiveness studies.",
author = "Goldstein, {Daniel A.} and Qiushi Chen and Turgay Ayer and Howard, {David H.} and Joseph Lipscomb and Harvey, {R. Donald} and El-Rayes, {Bassel F.} and Flowers, {Christopher R.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.clcc.2014.09.007",
language = "English (US)",
volume = "13",
pages = "219--225",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "4",

}

Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in folfox chemotherapy for metastatic colorectal cancer. / Goldstein, Daniel A.; Chen, Qiushi; Ayer, Turgay; Howard, David H.; Lipscomb, Joseph; Harvey, R. Donald; El-Rayes, Bassel F.; Flowers, Christopher R.

In: Clinical Colorectal Cancer, Vol. 13, No. 4, 01.01.2014, p. 219-225.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in folfox chemotherapy for metastatic colorectal cancer

AU - Goldstein, Daniel A.

AU - Chen, Qiushi

AU - Ayer, Turgay

AU - Howard, David H.

AU - Lipscomb, Joseph

AU - Harvey, R. Donald

AU - El-Rayes, Bassel F.

AU - Flowers, Christopher R.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Dosing chemotherapy based on pharmacokinetics (PK) instead of body surface area (BSA) has been shown to decrease interindividual variability in drug exposure. PK-guided 5-fluorouracil (5-FU) instead of BSA-guided 5- FU for patients with metastatic colorectal cancer (mCRC) leads to decreased toxicity and increased overall survival (OS). In this article, we use Markov modeling to show that this is a cost-effective strategy, costing $23,000 per quality-adjusted life-year (QALY) gained. Background: Dosing chemotherapy based on BSA results in marked interindividual variability in drug exposure. A randomized trial showed increased OS and decreased toxicity with PK-guided compared with BSA-based 5-FU dosing in patients with mCRC. The objective of this study was to compare the cost effectiveness of PK-based 5- FU dosing with BSA-based 5-FU dosing in patients with mCRC receiving FOLFOX (5-FU, leucovorin, and oxaliplatin). Materials and Methods: We developed a Markov model to evaluate the cost effectiveness of PK FOLFOX compared with BSA FOLFOX. Progression risks and cause-specific mortality were extrapolated from the fitted survival models. Costs for administration and management of adverse events were estimated based on 2013 Medicare reimbursement rates and average sale prices. Results: PK FOLFOX provided 2.03 QALYs at a cost of $50,205 compared with BSA FOLFOX, which provided 1.46 QALYs at a cost of $37,173. The incremental cost-effectiveness ratio (ICER) was $22,695 per QALY. The ICER remained < $50,000 per QALY in all univariate and multivariate sensitivity analyses. Conclusion: At a $50,000 per QALY threshold, PK FOLFOX is cost effective for mCRC. Because of the cost effectiveness profile and OS advantage with PK FOLFOX, it should be evaluated further in comparative effectiveness studies.

AB - Dosing chemotherapy based on pharmacokinetics (PK) instead of body surface area (BSA) has been shown to decrease interindividual variability in drug exposure. PK-guided 5-fluorouracil (5-FU) instead of BSA-guided 5- FU for patients with metastatic colorectal cancer (mCRC) leads to decreased toxicity and increased overall survival (OS). In this article, we use Markov modeling to show that this is a cost-effective strategy, costing $23,000 per quality-adjusted life-year (QALY) gained. Background: Dosing chemotherapy based on BSA results in marked interindividual variability in drug exposure. A randomized trial showed increased OS and decreased toxicity with PK-guided compared with BSA-based 5-FU dosing in patients with mCRC. The objective of this study was to compare the cost effectiveness of PK-based 5- FU dosing with BSA-based 5-FU dosing in patients with mCRC receiving FOLFOX (5-FU, leucovorin, and oxaliplatin). Materials and Methods: We developed a Markov model to evaluate the cost effectiveness of PK FOLFOX compared with BSA FOLFOX. Progression risks and cause-specific mortality were extrapolated from the fitted survival models. Costs for administration and management of adverse events were estimated based on 2013 Medicare reimbursement rates and average sale prices. Results: PK FOLFOX provided 2.03 QALYs at a cost of $50,205 compared with BSA FOLFOX, which provided 1.46 QALYs at a cost of $37,173. The incremental cost-effectiveness ratio (ICER) was $22,695 per QALY. The ICER remained < $50,000 per QALY in all univariate and multivariate sensitivity analyses. Conclusion: At a $50,000 per QALY threshold, PK FOLFOX is cost effective for mCRC. Because of the cost effectiveness profile and OS advantage with PK FOLFOX, it should be evaluated further in comparative effectiveness studies.

UR - http://www.scopus.com/inward/record.url?scp=84922631822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922631822&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2014.09.007

DO - 10.1016/j.clcc.2014.09.007

M3 - Article

VL - 13

SP - 219

EP - 225

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 4

ER -